Therapeutic Potential of Mitotic Kinases’ Inhibitors in Cancers of the Gastrointestinal System

Mitosis entails mechanistic changes required for maintaining the genomic integrity in all dividing cells. The process is intricate and temporally spatially regulated by ordered series of activation de-activation protein kinases. mitotic kinases ensure stepwise progression entry into mitosis after G2 phase cell cycle, followed prophase, pro-metaphase, metaphase, anaphase, telophase, subsequently cytokinesis birth two daughter cells with equal segregation distribution genome. major include cyclin-dependent kinase 1 (CDK1), Aurora A B Kinases, Polo-Like-Kinase (PLK1), among others. Overexpression some these has been reported many cancers as fidelity genome are interlinked dependent on regulators, native irregularities factors can be targeted therapeutic strategies various cancers. Here, we report summarize recent updates literature describing inhibitors targeting kinases, which used potential interventions gastrointestinal including gastric cancer, liver pancreatic cancer colorectal cancer.